1. Home
  2. ATGL vs MGNX Comparison

ATGL vs MGNX Comparison

Compare ATGL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Technology Group Limited

ATGL

Alpha Technology Group Limited

N/A

Current Price

$11.00

Market Cap

241.3M

Sector

N/A

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.33

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATGL
MGNX
Founded
2017
2000
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
241.3M
220.6M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
ATGL
MGNX
Price
$11.00
$4.33
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.3K
1.3M
Earning Date
01-27-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.01
$1.30
52 Week High
$50.00
$5.08

Technical Indicators

Market Signals
Indicator
ATGL
MGNX
Relative Strength Index (RSI) 37.70 49.98
Support Level $10.52 $1.49
Resistance Level $16.08 $4.55
Average True Range (ATR) 0.82 0.38
MACD 0.02 -0.04
Stochastic Oscillator 8.49 36.57

Price Performance

Historical Comparison
ATGL
MGNX

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: